Orexin-A
A neuropeptide that regulates wakefulness, arousal, and appetite. Its deficiency causes narcolepsy.
What is Orexin-A?
Orexin-A (also called Hypocretin-1) is a 33-amino acid neuropeptide produced by neurons in the lateral hypothalamus. It is a master regulator of the sleep-wake cycle, arousal, and energy homeostasis. Loss of orexin-producing neurons causes narcolepsy type 1. Research into orexin replacement therapy and orexin receptor agonists is active.
What Orexin-A Is Investigated For
Orexin-A is the endogenous wakefulness-promoting neuropeptide whose loss causes narcolepsy type 1, and research interest centers on replacement therapy for narcolepsy, promotion of alertness and wakefulness, and to a lesser extent metabolic and appetite regulation. The strongest mechanistic case is in narcolepsy type 1 — where orexin deficiency is the defining pathology — and small intranasal studies have reported acute improvements in sleep, attention, and olfaction in narcoleptic patients. The translational future of orexin pharmacology has shifted decisively to oral small-molecule OX2R agonists: Takeda's oveporexton (TAK-861) is described in the peer-reviewed literature as approved for narcolepsy type 1 following its Phase 3 program (Sun & Gao, Drug Discov Ther August 2026, PMID 42618292), and Alkermes' alixorexton reported a positive Vibrance-1 Phase 2 RCT in Lancet Neurology August 2026 (PMID 42636845) with placebo-corrected MWT gains of ~22–26 minutes across 4/6/8 mg doses, meaningfully broadening the OX2R class beyond a single molecule. Peptide-based orexin-A as a chronic replacement therapy has not advanced through controlled long-term human trials and is now competing against a much more practical and validated small-molecule path. Use in healthy adults for cognition or alertness has no rigorous clinical basis, and exogenous augmentation raises plausible cardiovascular and sympathetic concerns given orexin's pressor effects — with the additional caveat that a 2026 Analytical Chemistry LC-MS/MS methods paper (PMID 42118575) demonstrated that widely-cited plasma/serum orexin biomarker levels are analytical artifacts, so the peripheral-orexin correlation literature must be read with far greater caution than the pre-2026 field assumed. Active drug-development target, not an established therapy.
History & Discovery
Orexin-A — also called hypocretin-1 — was discovered in 1998 by two independent research groups within weeks of each other. Luis de Lecea and J. Gregor Sutcliffe at the Scripps Research Institute identified the peptides via subtractive hybridization for hypothalamic-specific transcripts and named them 'hypocretins' for their hypothalamic origin and structural relationship to the secretin peptide family. Almost simultaneously, Takeshi Sakurai and Masashi Yanagisawa at UT Southwestern identified the same peptides as ligands for orphan G-protein-coupled receptors and named them 'orexins,' from the Greek for appetite, based on their initial observation that intracerebroventricular injection increased food intake in rats. Both names persist in the literature; 'orexin' tends to dominate clinical neurology and 'hypocretin' tends to dominate basic neuroscience. The field's defining moment came two years later. In 2000, Emmanuel Mignot's group at Stanford and Christian Bassetti's collaborators showed that human narcolepsy with cataplexy is associated with severe loss of orexin-producing neurons in the lateral hypothalamus, and that cerebrospinal fluid orexin-A is essentially undetectable in those patients. That single finding redefined narcolepsy type 1 as an orexin-deficiency disorder and reframed the orexin system as a therapeutically tractable target for both wake-promoting and sleep-promoting drug development. The first wave of clinical translation went in the antagonist direction: dual orexin receptor antagonists (DORAs) — suvorexant, lemborexant, daridorexant — became approved insomnia drugs in the 2010s and early 2020s. The second wave, now the dominant area of clinical work, is in orexin agonists. Takeda's oveporexton (TAK-861) is described in the peer-reviewed literature as approved for narcolepsy type 1 following its Phase 3 program — a Drug Discov Ther August 2026 review by Sun and Gao (PMID 42618292) labels oveporexton the 'first-in-class orexin receptor 2 (OX2R) agonist approved for treatment of narcolepsy type 1' — cementing an OX2R-agonist future for orexin-deficient hypersomnolence. Alkermes reported a positive Phase 2 for alixorexton (Vibrance-1, Lancet Neurology August 2026, PMID 42636845) with placebo-corrected MWT gains of roughly 22–26 minutes across 4/6/8 mg dose arms — the second Phase 2-positive OX2R agonist, broadening the class beyond a single molecule. Centessa's ORX750 remains in development. Intranasal orexin-A as a peptide replacement therapy was tested in narcolepsy in small studies in the 2000s and 2010s but has been comprehensively overtaken by the small-molecule oral agonist program. Separately, a 2026 Analytical Chemistry paper (PMID 42118575) established that widely-reported plasma and serum orexin-A concentrations are analytical artifacts — real peripheral concentrations are below the limit of detection — invalidating the interpretability of much of the pre-2026 'peripheral orexin as biomarker' clinical literature.
How It Works
Orexin-A is the brain's 'wake-up signal.' It activates arousal centers throughout the brain, keeping you alert and awake. When orexin neurons are destroyed (as in narcolepsy), people experience uncontrollable sleepiness.
Orexin-A binds to both OX1R and OX2R (orexin receptors 1 and 2), which are GPCRs expressed widely in the brain including the locus coeruleus, tuberomammillary nucleus, raphe nuclei, and ventral tegmental area. It activates noradrenergic, histaminergic, serotonergic, and dopaminergic arousal systems. OX2R is particularly important for sleep-wake regulation. Orexin-A also regulates the HPA axis, sympathetic tone, and energy metabolism. It has a disulfide bond that stabilizes its structure and distinguishes it from Orexin-B.
Evidence Snapshot
Human Clinical Evidence
Limited but growing for orexin-A peptide itself; substantial for the broader orexin agonist class. Intranasal orexin-A studies in narcolepsy patients show acute promise. Oral OX2R agonist Phase 2 cognition data in NT1 (oveporexton, JAMA Neurology 2026) and ongoing Phase 3 programs for TAK-861/oveporexton and ORX750 are reshaping the field toward small-molecule successors.
Animal / Preclinical
Extensive. Orexin biology is well-characterized in animal models.
Mechanistic Rationale
Very strong. Orexin system's role in sleep-wake regulation is thoroughly established.
Research Gaps & Open Questions
What the current literature has not yet settled about Orexin-A:
- 01Chronic intranasal orexin-A safety and efficacy in narcolepsy — small acute studies exist, but no controlled long-term replacement-therapy trial has been completed and the small-molecule OX2R-agonist path (oveporexton approved per PMID 42618292; alixorexton Phase 2 positive per PMID 42636845) has effectively displaced the peptide-replacement rationale.
- 02Whether peptide-based orexin-A retains any niche given the OX2R-agonist class validation — most plausibly in specialty settings where oral OX2R agonist tolerability, cost, or availability is a limiter; no head-to-head trials exist.
- 03How much of the pre-2026 peripheral-orexin biomarker literature survives the finding that plasma/serum orexin-A concentrations reported in the ng/mL range are analytical artifacts (Cao et al., Anal Chem 2026, PMID 42118575) — a systematic re-audit of prior claims linking peripheral orexin-A to cardiovascular, metabolic, and hormonal outcomes is warranted.
- 04Use in narcolepsy type 2 and idiopathic hypersomnia — most data is in narcolepsy type 1 (orexin-deficient by definition), and whether exogenous orexin helps conditions where the orexin system is intact is unclear.
- 05Cardiovascular safety with chronic use — orexin's sympathoexcitatory effects raise long-term cardiovascular concerns that have not been studied across years of replacement.
- 06Use in healthy adults for cognition or alertness — there is no rigorous clinical evidence that exogenous orexin-A meaningfully enhances wakefulness or cognition in non-deficient individuals, and the safety basis for off-label use is absent.
- 07Reproductive, pediatric, and pregnancy data — no studies in any of these populations.
Forms & Administration
Intranasal spray (research). Oral orexin receptor agonists are in clinical development. Not widely available outside research settings.
Dosing & Protocols
The ranges below reflect protocols commonly discussed in the literature and by clinicians — not a prescription. Actual dosing for any individual should be determined by a qualified healthcare provider who knows the patient.
Typical Range
Intranasal orexin-A research doses in narcolepsy studies have been on the order of 1 mg per nostril (roughly 2 mg total per dose), administered as a single dose in acute studies. There is no approved orexin-A product, no established therapeutic dose range, and no over-the-counter or compounded product with validated content. Research-chemical intranasal orexin-A sold for self-experimentation has no dosing basis whatsoever.
Frequency
In the small published research protocols, single intranasal doses have been used to measure acute effects on sleepiness, attention, and olfaction in narcolepsy patients. No regimen for chronic daily replacement has been established in humans. The orexin system has a strong circadian rhythm with naturally high orexin-A activity during the active period and low activity during sleep, which is part of what makes scheduling difficult for any chronic dosing approach.
Timing Considerations
No specific timing requirements: can be administered at any time of day, with or without food, and is not tied to exercise timing. Consistency matters more than the specific clock — dose at roughly the same time each day (or same day each week, for weekly protocols) to keep exposure steady.
Cycle Length
Not characterized. There is no human regulatory approval and no chronic-use safety data for orexin-A as a replacement therapy. Acute research dosing has been single-dose or short-duration only.
Protocol Notes
Orexin-A is a 33-amino-acid peptide with two intramolecular disulfide bonds that are essential for biological activity. It does not cross the blood-brain barrier well via systemic administration, which is why intranasal delivery (using olfactory and trigeminal pathways to the CNS) has been the route used in the few human studies. Subcutaneous or intravenous administration would not be expected to reproduce the central effects. The broader therapeutic future of orexin pharmacology is not in injected or intranasal orexin-A peptide. It is in oral small-molecule orexin receptor agonists — TAK-861/oveporexton, ORX750, and successor compounds — which are designed to engage OX2R selectively, achieve oral bioavailability, and cross the blood-brain barrier. Phase II and III data in narcolepsy type 1 published in 2024–2025 has been notable, with several reports of normalization of wakefulness measures in patients who had been refractory to existing wake-promoting agents. For people interested in orexin biology for narcolepsy, the practical path is through clinical trials of these oral agonists or through approved follow-on drugs as they reach market — not through self-administered intranasal orexin-A peptide of unverified provenance.
Orexin-A is not approved for any therapeutic indication anywhere. It is a research peptide and a target of active drug development, not a treatment. Self-administered intranasal orexin-A from research-chemical sources carries unknown content, unknown sterility, and no dose-response basis in humans.
Timeline of Effects
Onset
In published intranasal orexin-A studies in narcolepsy patients, acute alertness and attentional effects have been reported within 30–60 minutes of administration. No data exists for non-narcoleptic users.
Peak Effect
Peak subjective and measured effects in the small intranasal narcolepsy studies have been described in the 1–3 hour window post-dose, consistent with the relatively short central residence time of the peptide.
After Discontinuation
Acute effects fade within hours of a single dose. Because orexin-A has not been used in humans as chronic replacement therapy, there is no characterization of post-discontinuation rebound or withdrawal. Endogenous orexin signaling is constitutive in healthy adults, so transient exogenous augmentation in a narcoleptic patient would not be expected to suppress an axis the way exogenous opioids or steroids might.
Common Questions
Can orexin-A treat narcolepsy?
Potentially. Narcolepsy type 1 is caused by loss of orexin neurons. Intranasal orexin-A has shown promise in animal models and early human studies for restoring wakefulness. Orexin receptor agonists are in clinical development.
How is orexin-A different from suvorexant and the other prescription insomnia drugs?
Opposite direction. Suvorexant, lemborexant, and daridorexant are dual orexin receptor antagonists that block the orexin receptors to promote sleep. Orexin-A is the endogenous agonist that activates those receptors to promote wakefulness. The insomnia DORAs were developed specifically because blocking orexin signaling induces sleep — which is the same reason orexin agonists are being developed for narcolepsy.
Will oral OX2R agonists replace intranasal orexin-A?
Effectively yes for narcolepsy type 1. Takeda's oveporexton (TAK-861) is described in the peer-reviewed literature as approved for narcolepsy type 1 following its Phase 3 program (Drug Discov Ther August 2026, PMID 42618292); a 2026 JAMA Neurology Phase 2 RCT (PMID 41359331) had already shown oveporexton improved attention, memory, and executive function over 8 weeks in NT1 patients. Alkermes' selective OX2R agonist alixorexton reported a positive Phase 2 Vibrance-1 trial in Lancet Neurology August 2026 (PMID 42636845), and Centessa's ORX750 remains in development — so the class is now genuinely a class rather than a single molecule. Oral dosing, blood-brain-barrier penetration, and OX2R selectivity give the small-molecule path decisive practical advantages over peptide replacement.
Is intranasal orexin-A safe for healthy people to use for alertness or cognition?
There is no rigorous clinical evidence that exogenous orexin-A enhances wakefulness or cognition in non-deficient adults, and the safety basis for off-label use is absent. A pilot study in healthy men showed intranasal orexin-A modulates sympathetic vascular tone, raising plausible cardiovascular concerns. Research-chemical product is unverified for content, sterility, and stability. Self-administered intranasal use for nootropic purposes is fringe and unsupported.
Who Orexin-A Is NOT For
- •Pregnancy — no human pregnancy or reproductive-toxicology data; the orexin system is involved in fetal hypothalamic development and energy regulation and exogenous augmentation is not characterized.
- •Breastfeeding — no data on milk transfer or infant exposure.
- •Pediatric use outside research settings — orexin signaling is developmentally regulated and no pediatric safety data exists.
- •Cardiovascular instability — orexin-A increases sympathetic tone, blood pressure, and heart rate in animal models and in healthy human pilot work, so use in patients with uncontrolled hypertension, recent myocardial infarction, arrhythmia, or other unstable cardiovascular disease is mechanistically inadvisable.
- •Active anxiety or panic disorder — orexin signaling is implicated in panic attack physiology and CO2-induced panic in animal models; exogenous augmentation could plausibly worsen anxiety symptoms.
- •Concurrent use of dual orexin receptor antagonists (suvorexant, lemborexant, daridorexant) — directly opposing pharmacology.
Drug & Supplement Interactions
Documented clinical drug interactions for orexin-A in humans are limited because human use is limited. The most concrete interaction is conceptual rather than empirical: dual orexin receptor antagonists (DORAs — suvorexant, lemborexant, daridorexant) are designed to block exactly the receptors orexin-A activates. Co-use would be pharmacologically self-defeating and is not described in any clinical context. Patients on a DORA for insomnia should not be exposed to exogenous orexin-A. With stimulants and other wake-promoting agents (modafinil, armodafinil, amphetamines, methylphenidate, solriamfetol, pitolisant), the additive arousal and cardiovascular load is plausible but not formally characterized. Cardiovascular stimulation from orexin-A on top of these drugs could produce additive blood pressure and heart rate effects. With antihypertensives and rate-control medications, orexin-A's sympathetic activation could partially offset their effect. With opioids and benzodiazepines (which suppress orexin signaling indirectly via central depression), the interaction direction is unpredictable in humans. As with any peptide of unverified clinical pharmacology, patients on regular medications should disclose any orexin-A use to their prescriber. Absence of documented interaction reflects absence of human use rather than absence of risk.
Safety Profile
Common Side Effects
Cautions
- • Not FDA-approved
- • Very limited human safety data
- • May affect blood pressure and heart rate
What We Don't Know
Human safety profile is not well-established. Most data comes from animal studies and the inverse pharmacology of orexin receptor antagonists (sleep drugs like suvorexant).
Legal Status
United States
Orexin-A the peptide is not FDA-approved for any therapeutic indication. It is not a controlled substance. As a research peptide, it is sold by research-chemical and reference-standard suppliers but is not authorized for human use. The small-molecule OX2R agonist landscape has shifted materially in 2026: a Drug Discov Ther August 2026 review (PMID 42618292) describes Takeda's oveporexton (TAK-861) as the first-in-class OX2R agonist approved for narcolepsy type 1 following its Phase 3 program, and Alkermes' selective OX2R agonist alixorexton reported a positive Vibrance-1 Phase 2 RCT (Lancet Neurology August 2026, PMID 42636845) supporting further development. Dual orexin receptor antagonists (suvorexant, lemborexant, daridorexant) — which act in the opposite direction — remain FDA-approved for insomnia.
International
Orexin-A peptide is not approved as a medicine by EMA, MHRA, TGA, PMDA, or Health Canada. The oveporexton (TAK-861) OX2R agonist program's approval status internationally is jurisdiction-specific; the Drug Discov Ther August 2026 review (PMID 42618292) frames it as approved based on the Phase 3 global program, though specific regulatory-agency approval dates vary by market. Alixorexton (Alkermes) is in Phase 3 progression following Vibrance-1. Dual orexin receptor antagonists remain widely approved for insomnia in this period across major markets.
Sports & Competition
Orexin-A is not currently named on the WADA Prohibited List. WADA's S0 'non-approved substances' clause arguably applies, since orexin-A is not approved for human therapeutic use anywhere. Given that endogenous orexin-A drives wakefulness and arousal, exogenous use for performance purposes raises plausible concerns under both S0 and stimulant-like considerations, even without explicit listing. Athletes should treat it as prohibited absent specific guidance.
Regulatory status changes over time. Verify current local rules with a qualified professional.
Myths & Misconceptions
Myth
Orexin-A is the same kind of drug as suvorexant or lemborexant.
Reality
It is the opposite. Suvorexant, lemborexant, and daridorexant are dual orexin receptor antagonists used for insomnia — they block orexin signaling. Orexin-A is the endogenous agonist that activates those receptors to promote wakefulness. The DORAs were developed precisely because blocking the orexin system promotes sleep.
Myth
Intranasal orexin-A is a proven narcolepsy treatment.
Reality
Intranasal orexin-A has been tested in small narcolepsy studies with biologically interesting acute effects, but it is not an approved treatment anywhere. The mainstream clinical translation has shifted to oral small-molecule OX2R agonists, which are in late-phase trials and likely to dominate the future of orexin-targeted narcolepsy therapy.
Myth
Orexin-A from research-chemical suppliers is a viable nootropic for healthy people.
Reality
There is no clinical evidence supporting orexin-A use for cognitive enhancement in healthy adults. Healthy individuals already have a fully functional orexin system; augmenting it pharmacologically has unknown risk. Research-chemical product is unverified for content, sterility, and stability, and the peptide does not survive oral administration. Self-administered intranasal use without medical supervision is fringe and unsupported.
Myth
Because orexin-A is endogenous, it is safe to administer.
Reality
Endogenous origin is not a safety property. Endogenous orexin-A is released in tightly regulated, pulsatile, circadian patterns at concentrations the brain has evolved to handle. Bolus exogenous administration in non-physiologic patterns has cardiovascular, sympathetic, and behavioral effects that have not been characterized in humans outside narrow research contexts.
Myth
Loss of orexin causes narcolepsy, so taking orexin will fix it.
Reality
Narcolepsy type 1 is caused by autoimmune destruction of orexin-producing neurons, and replacement of orexin signaling is a logical strategy — that is the rationale for the OX2R agonist program. But the clinical translation is not as simple as 'inject orexin and the disease resolves.' The peptide's pharmacokinetics, route limitations, and the chronic nature of the deficit make oral small-molecule agonists a more practical path, and even those are still in trials.
Published Research
20 studiesSafety, tolerability, and efficacy of alixorexton, a selective orexin 2 receptor agonist for narcolepsy type 1 (Vibrance-1): a randomised, double-blind, placebo-controlled, phase 2 trial.
Lancet Neurology August 2026 Phase 2 RCT of Alkermes' selective OX2R agonist alixorexton in narcolepsy type 1 (Vibrance-1) — placebo-corrected mean sleep latency on the Maintenance of Wakefulness Test improved by roughly 22–26 minutes across 4/6/8 mg doses. The second Phase 2-positive OX2R agonist after oveporexton, meaningfully broadening the OX2R class beyond a single-molecule story and supporting Phase 3 progression.
Oveporexton: The first-in-class orexin receptor 2 (OX2R) agonist approved for treatment of narcolepsy type 1 (NT1).
Recent Advances and Emerging Pharmacotherapeutic Approaches for Central Hypersomnolence Disorders.
Orexin, Sleep, and Cognition in Alzheimer Disease: Non-REM Oscillatory Activity and Neural Resilience.
Tackling the Orexin Conundrum: An Optimized LC-MS/MS Method Demonstrates Accurate CSF Quantification and Absence in Peripheral Blood.
Analytical Chemistry May 2026. An optimized LC-MS/MS method for orexin-A demonstrates that widely-reported plasma and serum orexin-A concentrations in the ng/mL range are analytical artifacts — true peripheral concentrations are below 0.1 pg/mL and effectively undetectable. Directly undermines the interpretability of the large body of 'plasma orexin as biomarker' clinical literature and justifies a much more conservative reading of any peripheral-orexin correlation study.
Orexin receptor 2 agonists: a pathophysiologic approach to narcolepsy type 1
Effects of Oveporexton, an Orexin Receptor 2-Selective Agonist, on Cognition in Narcolepsy Type 1
JAMA Neurology 2026 Phase 2 RCT of oral OX2R-selective agonist oveporexton (TAK-861) in narcolepsy type 1, demonstrating improved attention, memory, and executive function over 8 weeks. The cognition outcomes — beyond wakefulness alone — meaningfully extend the case for oral OX2R agonists as the practical successor to peptide-replacement approaches for orexin-deficient narcolepsy.
Orexin Deficiency in Narcolepsy: Molecular Mechanisms, Clinical Phenotypes, and Emerging Therapeutic Frontiers
Exploring the role of Orexin-A neuropeptide in Parkinson's disease: A systematic review and meta-analysis
Oral Orexin Receptor 2 Agonist in Narcolepsy Type 1
Safety and pharmacodynamics of a single infusion of danavorexton in adults with idiopathic hypersomnia
Intranasal orexin A modulates sympathetic vascular tone: a pilot study in healthy male humans
Orexin-A in Patients With Lewy Body Disease: A Systematic Review and Meta-Analysis
Cerebrospinal fluid orexin in Alzheimer's disease: a systematic review and meta-analysis
Associations of plasma hypocretin-1 with metabolic and reproductive health: Two systematic reviews of clinical studies
The effect of intranasal orexin-A (hypocretin-1) on sleep, wakefulness and attention in narcolepsy with cataplexy
Effects of intranasal hypocretin-1 (orexin A) on sleep in narcolepsy with cataplexy
Olfactory dysfunction in patients with narcolepsy with cataplexy is restored by intranasal Orexin A (Hypocretin-1)
Narcolepsy and the hypocretin system--where motion meets emotion
Hypocretin (orexin) deficiency in narcolepsy and primary hypersomnia
Quick Facts
- Class
- Neuropeptide
- Tier
- D
- Evidence
- Emerging
- Safety
- Limited Data
- Updated
- Sep 2026
- Citations
- 20PubMed
Also known as
Tags
Related Goals
Evidence Score
Clinical Trials
View Clinical TrialsLinks to ClinicalTrials.gov for reference. Listing does not imply endorsement.